Editions 2023 de l’ASCO et l’EHA
Le congrès de l’American Society of Clinical Oncology s’est tenu du 02 au 06 juin 2023 à Chicago aux Etats-Unis et celui de l’European Hematology Association du 08 au 11 juin 2023 à Francfort en Allemagne.
Retrouvez les posters et communications orales qui ont été présentés aux éditions 2023 de l’ASCO et l’EHA.
| Communication orale | ASCO 2023 |
|---|---|
| Clémentine Sarkozy | Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study |
| Communications orales | EHA 2023 |
|---|---|
| Amira Marouf | Efficacy of anti-PD1 therapy in relapsed or refractory NK/T cell Lymphoma: a matched cohort analysis from the LYSA |
| Roch Houot | Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Final Analysis of ALYCANTE, a Phase 2 LYSA Study |
| Romain Loyaux | Clonal architecture of relapsed or refractory Angioimmunoblastic T-Cell Lymphoma: an ancillary study of the ORACLE trial, a LYSA study |
| Posters | EHA 2023 |
|---|---|
| Samuel Vic | Transfusion needs after CD19 CAR T-cells for large B-cell lymphoma: predictive factors and impact on outcome. A DESCAR-T study |
| Marie-Hélène Delfau-Larue | Early ctDNA clearance after CAR T-cell infusion predicts outcome in patients with Large B-cell lymphoma : results from ALYCANTE, a phase 2 LYSA study |
| Clémentine Sarkozy | Very Long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study |
